United Therapeutics Co. (NASDAQ:UTHR) Director Martine A. Rothblatt Sells 1,468 Shares

United Therapeutics Co. (NASDAQ:UTHRGet Free Report) Director Martine A. Rothblatt sold 1,468 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $275.85, for a total transaction of $404,947.80. Following the transaction, the director now owns 130 shares in the company, valued at approximately $35,860.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $276.44 on Thursday. The firm has a fifty day moving average price of $245.78 and a two-hundred day moving average price of $233.38. The company has a market cap of $12.26 billion, a PE ratio of 13.07, a price-to-earnings-growth ratio of 4.17 and a beta of 0.54. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $279.98. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period last year, the firm earned $4.86 EPS. Analysts expect that United Therapeutics Co. will post 24.2 EPS for the current year.

Analyst Upgrades and Downgrades

UTHR has been the topic of several analyst reports. Oppenheimer increased their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 16th. Wedbush reaffirmed an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $309.44.

Read Our Latest Stock Analysis on United Therapeutics

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC lifted its holdings in shares of United Therapeutics by 13,769.2% during the 4th quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock worth $1,982,000 after acquiring an additional 8,950 shares during the period. DekaBank Deutsche Girozentrale increased its position in shares of United Therapeutics by 54.4% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock worth $20,617,000 after purchasing an additional 33,338 shares in the last quarter. Nordea Investment Management AB increased its position in shares of United Therapeutics by 155.2% during the 4th quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock worth $8,427,000 after purchasing an additional 23,532 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of United Therapeutics by 90.3% during the 4th quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock worth $12,200,000 after purchasing an additional 26,325 shares in the last quarter. Finally, Duality Advisers LP increased its position in shares of United Therapeutics by 56.1% during the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock worth $3,440,000 after purchasing an additional 5,622 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.